Recent News

• 06.12.2026 - HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
• 05.22.2026 - HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
• 05.21.2026 - HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
• 04.29.2026 - HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
• 04.09.2026 - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
• 03.23.2026 - HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
• 03.09.2026 - HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
• 03.06.2026 - Intended Retirement of Independent Non-executive Director and changes of composition of board committees
• 03.05.2026 - HUTCHMED Reports 2025 Full Year Results and Business Updates
• 03.04.2026 - HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Recent Filings

• 06.12.2026 - EX-99.1 EX-99.1
• 06.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.09.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 06.05.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.22.2026 - EX-99.1 EX-99.1
• 05.22.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2026 - EX-99.1 EX-99.1
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]